Twist Bioscience Corp — Director's Dealing 2021

Aug 14, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Twist Bioscience Corp (TWST)
CIK: 0001581280
Period of Report: 2021-08-12

Reporting Person: CRANDELL KEITH (Director)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-08-12	Common Stock	S	1412	$106.93	Disposed	486	Direct
2021-08-12	Common Stock	S	41033	$106.9765	Disposed	78602	Indirect
2021-08-12	Common Stock	S	2555	$107.5638	Disposed	76047	Indirect
2021-02-11	Common Stock	J	286480	—	Disposed	440354	Indirect
2021-02-11	Common Stock	J	14560	—	Acquired	97252	Indirect
2021-02-11	Common Stock	J	113520	—	Disposed	174584	Indirect
2021-02-11	Common Stock	J	1	—	Acquired	97253	Indirect
2021-05-13	Common Stock	J	214828	—	Disposed	225526	Indirect
2021-05-13	Common Stock	J	10918	—	Acquired	108171	Indirect
2021-05-13	Common Stock	J	85172	—	Disposed	89412	Indirect
2021-05-13	Common Stock	J	1	—	Acquired	108172	Indirect
2021-05-19	Common Stock	J	225526	—	Disposed	0	Indirect
2021-05-19	Common Stock	J	11462	—	Acquired	119634	Indirect
2021-05-19	Common Stock	J	89412	—	Disposed	0	Indirect
2021-05-19	Common Stock	J	1	—	Acquired	119635	Indirect

Footnotes

F1: Pro-rata distribution of Common Stock held by a limited partnership to its partners for no consideration.

F2: The shares were directly held by ARCH Venture Fund VII, L.P. ("ARCH Fund VII"). The sole general partner of ARCH Fund VII is ARCH Venture Partners VII, L.P. ("ARCH Partners VII"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. The sole general partner of ARCH Partners VII is ARCH Venture Partners VII, LLC ("ARCH VII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Fund VII. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

F3: The shares were directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). The sole general partner of ARCH Overage is ARCH Venture Partners VIII, LLC ("ARCH VIII LLC"), which may be deemed to be the beneficial owner of the shares held by ARCH Overage. ARCH VIII LLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

F4: Keith Crandell is a managing director of ARCH VII LLC and ARCH VIII LLC, and may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Mr. Crandell disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

F5: Change in form of ownership of shares previously reported as beneficially owned by the reporting person.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.39 to $107.37. The reporting person undertakes to provide to TWST, any security holder of TWST, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (6) and (7) to this Form 4.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.405 to $107.70.